Boston Scientific Corporation

Here Are Friday’s Top Wall Street Analyst Research Calls: Blackstone Mortgage, Boston Scientific, Edison International, Ford, GoDaddy, International Paper, Roblox, Saia, and More

After a week of wild swings that rattled portfolios and left investors guessing, Wall Street analysts are already reshuffling their ratings on Friday morning, with some surprising cuts and upgrades across sectors from utilities to gaming that could reshape how you think about your positions.

Yahoo Finance · 31/07/2026 · lire l'article ↗

Boston Scientific Lowered Full-Year Guidance on Headwinds in Electrophysiology, Watchman Portfolios, RBC Says

Boston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year

Yahoo Finance · 30/07/2026 · lire l'article ↗

BSX Q2 Earnings Call Highlights WATCHMAN and EP Pressure

BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and new product catalysts for future growth.

Yahoo Finance · 30/07/2026 · lire l'article ↗

What Are Wall Street Analysts' Target Price for Boston Scientific Stock?

Boston Scientific underperformed the broader market, though analysts remain optimistic, citing strong earnings execution, innovation, and meaningful upside from current levels.

Yahoo Finance · 30/07/2026 · lire l'article ↗

Boston Scientific (BSX) Stock Sees Modest Fair Value Cut As Watchman Concerns Reset Expectations

Analyst fair value for Boston Scientific has shifted from US$75.00 to US$72.25, pointing to a modest reset in price targets. This change lines up with recent research that lowers expectations for Watchman and electrophysiology while still recognizing strengths across the broader portfolio and generally positive ratings. As you read on, you will see how these moving targets, both bullish and bearish, shape the evolving Boston Scientific story and what to watch next. Stay updated as the Fair...

Yahoo Finance · 30/07/2026 · lire l'article ↗

Boston Scientific (BSX) Is Up 7.1% After Q2 Beat, Recall And Major Restructuring Plan - Has The Bull Case Changed?

Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...

Yahoo Finance · 30/07/2026 · lire l'article ↗